These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26769299)

  • 1. Expert consensus on maintenance treatment for metastatic colorectal cancer in China.
    Xu RH; Shen L; Li J; Xu JM; Bi F; Ba Y; Bai L; Shu YQ; Liu TS; Li YH; Bai CM; Yuan XL; Zhang J; Chen G; Zhou AP; Yuan Y; Wang XJ; Qian XP; Deng YH
    Chin J Cancer; 2016 Jan; 35():13. PubMed ID: 26769299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
    Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis.
    Ma H; Wu X; Tao M; Tang N; Li Y; Zhang X; Zhou Q
    Medicine (Baltimore); 2019 Dec; 98(50):e18227. PubMed ID: 31852082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
    Johnsson A; Hagman H; Frödin JE; Berglund A; Keldsen N; Fernebro E; Sundberg J; De Pont Christensen R; Garm Spindler KL; Bergström D; Jakobsen A
    Ann Oncol; 2013 Sep; 24(9):2335-41. PubMed ID: 23788755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
    Salvatore L; Bria E; Sperduti I; Hinke A; Hegewisch-Becker S; Aparicio T; Le Malicot K; Boige V; Koeberle D; Baertschi D; Dietrich D; Tortora G; Arnold D
    Cancer Treat Rev; 2021 Jun; 97():102202. PubMed ID: 33838596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
    Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
    Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
    Shi M; Ma T; Xi W; Jiang J; Wu J; Zhou C; Yang C; Zhu Z; Zhang J
    Trials; 2020 Mar; 21(1):249. PubMed ID: 32143730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer.
    Zhao L; Wang J; Li H; Che J; Cao B
    Oncotarget; 2016 May; 7(22):33418-28. PubMed ID: 27072579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.
    Stein A; Schwenke C; Folprecht G; Arnold D
    Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance strategy in metastatic colorectal cancer: A systematic review.
    Esin E; Yalcin S
    Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chinese expert consensus on multidisciplinary treatment of bone metastasis from colorectal cancer (2020 version)].
    Colorectal Oncology Committee of Chinese Medical Doctor Association
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):433-437. PubMed ID: 32575936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
    Sunakawa Y; Bekaii-Saab T; Stintzing S
    Cancer Treat Rev; 2016 Apr; 45():97-104. PubMed ID: 27002945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.
    Schwarz RE; Berlin JD; Lenz HJ; Nordlinger B; Rubbia-Brandt L; Choti MA
    HPB (Oxford); 2013 Feb; 15(2):106-15. PubMed ID: 23297721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
    Ron DA; Vera R; Labandeira CM; Manrique MCA; Núñez MÁ; Cid NG; Mata JG; Montes AF
    Clin Transl Oncol; 2020 Aug; 22(8):1205-1215. PubMed ID: 31898053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.
    Grávalos C; Carrato A; Tobeña M; Rodriguez-Garrote M; Soler G; Vieitez JM; Robles L; Valladares-Ayerbes M; Polo E; Limón ML; Safont MJ; Martínez de Castro E; García-Alfonso P; Aranda E;
    Clin Colorectal Cancer; 2018 Jun; 17(2):e323-e329. PubMed ID: 29551560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.